Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $17.33
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have earned a consensus rating of “Hold” from the six analysts that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month […]
More Stories
ST Germain D J Co. Inc. Has $12.10 Million Position in AbbVie Inc. (NYSE:ABBV)
ST Germain D J Co. Inc. raised its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.8% during the...
Seagate Technology Holdings plc (NASDAQ:STX) Shares Bought by CCM Investment Advisers LLC
CCM Investment Advisers LLC boosted its stake in shares of Seagate Technology Holdings plc (NASDAQ:STX – Free Report) by 2.8%...
IRADIMED Reports Record Revenues for Q4 2024 and Full-Year 2024
Iradimed Corporation (NASDAQ: IRMD), a company specializing in innovative Magnetic Resonance Imaging (MRI) compatible medical devices, has released its preliminary...
ST Germain D J Co. Inc. Purchases 306 Shares of McDonald’s Co. (NYSE:MCD)
ST Germain D J Co. Inc. raised its position in McDonald’s Co. (NYSE:MCD – Free Report) by 2.0% in the...
Wealth Enhancement Advisory Services LLC Increases Stake in Costco Wholesale Co. (NASDAQ:COST)
Wealth Enhancement Advisory Services LLC lifted its position in shares of Costco Wholesale Co. (NASDAQ:COST – Free Report) by 0.8%...
Challenger Energy Group (LON:CEG) Trading Up 12.4% – What’s Next?
Challenger Energy Group PLC (LON:CEG – Get Free Report) was up 12.4% on Friday . The stock traded as high...